4888.T
STELLA PHARMA CORPORATION
グロース · 医薬品 · 医薬品 · JP
JPY 358.00
+0.85%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 323.0M | 323.0M | 961.0M | 269.0M | 229.0M |
| Cost of Revenue | 12.6M | — | — | — | — |
| Gross Profit | 79.8M | 279.2M | 845.7M | 217.3M | 206.9M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 231.6M | 1.0B | 936.0M | 977.6M | 1.0B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 231.6M | 1.0B | 936.0M | 977.6M | 1.0B |
| Cost and Expenses | 1.1B | 1.1B | 1.1B | 1.0B | 1.0B |
| Operating Income (EBIT) | (748.0M) | (748.0M) | (90.0M) | (760.0M) | (806.0M) |
| Non-Operating | |||||
| Interest Income | — | 401.0K | 598.0K | 11.0K | 1.0K |
| Interest Expense | 1.5M | 7.3M | 4.1M | 2.1M | 2.6M |
| Net Interest Income | — | (6.9M) | (3.5M) | (2.1M) | (2.6M) |
| Other Non-Op Income/Expense | (4.1M) | (29.0M) | (47.6M) | 91.0K | 30.8M |
| Non-Operating Income (excl Interest) | 241.0K | 18.3M | 11.1M | 4.6M | 40.6M |
| EBT (Pre-Tax Income) | (156.0M) | (778.0M) | (137.9M) | (761.0M) | (776.0M) |
| Income Tax Expense | 712.0K | 2.9M | 2.9M | 2.8M | 2.9M |
| Bottom Line | |||||
| Net Income | (780.0M) | (780.0M) | (140.0M) | (763.0M) | (778.0M) |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (780.0M) | (780.0M) | (140.0M) | (763.0M) | (778.0M) |
| Per Share | |||||
| Basic EPS | (¥23) | (¥23) | (¥4) | (¥25) | (¥27) |
| Diluted EPS | (¥23) | (¥23) | — | — | — |
| Revenue Per Share | ¥9 | ¥9 | ¥29 | ¥9 | ¥8 |
| Shares | |||||
| Basic Shares Outstanding | 34.0M | 34.0M | 33.4M | 31.0M | 28.9M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | — | (719.4M) | (55.3M) | (725.0M) | (771.0M) |
| D&A | — | 28.6M | 34.7M | 35.0M | 35.0M |
| EBIT | (748.0M) | (748.0M) | (90.0M) | (760.0M) | (806.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026